Purpose: Prostate-specific antigen (PSA) has been used as a marker of advanced prostate cancer but remains controversial. To evaluate PSA as a predictor of survival, we analyzed data from sequential phase II trials of estramustine and etoposide.
RECENT STUDIES have suggested that several new agents and combinations may have significant activity In the treatment of patients with hormone-refractory prostate cancer. 13 Unfortunately, the interpretation of these reports and comparison of these agents and regimens is complicated by the difficulty in assessing response in this disease. This difficulty results from the fact that metastatic prostate cancer is primarily a disease of the bone. Changes in the structure and activity of bony lesions are difficult to assess with standard modalities. This problem has long plagued investigators who attempted to define new therapies for the treatment of metastatic prostate cancer. In the 1970s, investigators with the National Prostate Cancer Project conducted a series of trials that used response criteria that included stabilization of disease as a positive end point. 4 This approach has been widely criticized for inflating the percentage of responders to the chemotherapy regimens and has contributed to the skepticism as to whether chemotherapy has a role in the treatment of metastatic prostate cancer. 5 , 6 A more traditional approach has been to restrict phase II trials to patients with bidimensionally measurable disease. 7 Response in these patients can then be assessed by using standard criteria, such as a 50% reduction of the perpendicular diameters to constitute a partial response. be representative of the larger population of metastatic prostate cancer patients with bony disease m terms of tumor biology
The search for a reliable marker for the diagnosis of prostate cancer led to the dentification of and development of assays for prostate-specific antigen (PSA) PSA is a glycoprotein that is found almost exclusively in normal and neoplastic prostate cells and seminal fluid 89 Serum levels of PSA roughly correlate with the extent of disease.O Change in serum PSA level has been vahdated as a marker of response after surgery and radiation therapy for localized prostate cancer,"- ' 3 hormonal therapy for metastatic dis- have analyzed the prospectively collected PSA levels for patients enrolled onto two sequential phase II trials of the combination of estramustine and etoposide. The aim of these extended trials was to test the efficacy and antitumor activity of this combination in patients with metastatic hormonerefractory prostate cancer. The purpose of this analysis was to determine whether a change in serum PSA level could act as a marker for response m this disease after the admimstration of cytotoxic chemotherapy.
METHODS

Patients
Patients eligible for the sequential studies had histologically confirmed metastatic prostate cancer refractory to androgen deprivation, a Zubrod performance status (PS) of 3 or less, and had not received hormonal therapy (which included flutamide) or radiation therapy in the 4 weeks before initiation of therapy All patients had undergone surgical or medical castration, and at least one hormonal regimen had failed Patients who had undergone medical castration were not maintamed on their primary androgen suppression because estramustine s known to reliably induce castrate levels of testosterone. Patients on the first study were required to have undergone no pnor chemotherapy, whereas one pnor chemotherapy regimen was allowed in patients enrolled onto the second study. Written informed consent was obtained before study entry A medical history and physical examination with measurement of soft tissue disease. chest radiograph, computed tomographic scan of the abdomen and pelvis, bone scan, complete blood count, serum chemlstries, and PSA measurement by the Hybritech method (Hybntech, Inc. San Diego, CA) were performed
The initial trial consisted of estramustine (EMCYT, Pharmacia, Columbus, OH) 15 mg/kg daily in four divided doses and oral etoposlde (VP-16; VePesid, Bnstol Myers, Plainsboro, NJ) 50 mg/m 2 daily in two divided doses days I through 21 2 The doses were slightly modified for the second tnal to estramustme 10 mg/kg daily in three divided doses 24 Patients received therapy for 3 of every 4 weeks, and additional courses of treatment were administered as long as there was no evidence of disease progression and toxicity was tolerable Physical exammation, complete blood count, serum chemistries, and PSA levels were to be obtained before each treatment cycle, and assessment of measurable and assessable disease was performed after every other cycle (le, 8, 16, 24 , and 36 weeks, etc)
Statistical Methods
The change m PSA level relative to the pretreatment baseline PSA level was calculated at 4-week intervals For the purpose of comparing survival by change in PSA level, a landmark analysis 25 was conducted.
This method of measunng survival from a fixed time (landmark) by patient characteristics known at or before the landmark correctly addresses the length bias, which invalidates the standard methods when the patient characteristic changes over time A landmark of 8 weeks was selected for these survival analyses The univanate association of patient factors with survival from the landmark was assessed by the log-rank test and exarmned by Kaplan-Meier survival plots For patients with PSA measurements at both 4 and 8 weeks, the likelihood ratio test (LRT) was used to compare the additional predictive ablhty in a Cox model by adding the relative decrease n PSA level at a particular time from the model that contained PS alone We examined both a 50% or more and a 75% or more decrease in PSA level, as well as the relative change on a continuous scale, at 4 and 8 weeks Finally. after selecting the best PSA marker, the best overall predictive Cox regression model was determined in a backward model-building procedure based on the LRT. The model-building procedure starts with all factors considered and drops one-by-one the least predictive factor by using the LRT until only the factors considered significant at the 5% significance level remain. Patient factors considered as potential predictors were Zubrod PS, hemoglobin level. alkaline phosphatase level, baseline PSA level (log transformed), measurable disease (yes/no), and PSA marker Cut points for analysis of the laboratory vanables (hemoglobin and alkaline phosphatase levels) were established based on the normal ranges in the clinical laboratories at the University of Michigan Medical Center (Ann Arbor. MI) For the analysis of baseline PSA, we initially assessed three levels 20 ng/mL or less, 20 to 100 ng/mL, and 100 ng/mL or greater Because the latter two groups showed no difference in overall survival. they were combined for subsequent analyses PS was analyzed by the Zubrod scale, which was used for the original assessment The association between the achlevment of a soft tissue response and a 50% or more reduction in PSA level was evaluated among those patients with measurable disease by using Fisher's exact test
RESULTS
Patient Demographics
A total of 114 patients were enrolled onto these sequential studies. Available demographic data on all patients are listed in Table 1 . Sixteen patients had undergone radical retropubic prostatectomy. Sixty-four patients had previously been treated with radiotherapy; of these, 41 patients had received radiation therapy to the prostate as their primary therapy. Thirty-four patients had received palliative radiotherapy (11 patients had both primary and palhative radiation). Fifty patients received only one prior hormonal therapy The remainder received multiple prior hormonal treatments. Twenty-four patients had received prior chemotherapy. Forty-one patients had measurable soft-tissue disease, and the majority (29 patients) had lymph node involvement.
Data Analyzed
PSA levels were scheduled to be measured every 4 weeks per protocol. To allow for scheduling conflicts that would PSA AS A MARKER OF RESPONSE have prevented PSA levels from being drawn at exact intervals, the results of the PSA assay performed closest to the specified time point were considered performed at that time point In practical terms, this resulted in the inclusion of PSA levels from 2 weeks before to 2 weeks after the specified time point (ie, 2 to 6 weeks for the 4-week level, 6 to 10 weeks for the 8-week level). Despite these critena, several patients were excluded from the analysis because of lack of PSA data Eighty patients had a PSA value determined at 4 weeks, with 76% of these within 7 days of the target date Seventy-five patients had a PSA level determined at 8 weeks. with 71% of these within 7 days of the scheduled date. PSA levels were available at 4 weeks but not at 8 weeks for 18 patients, and at 8 weeks but not at 4 weeks for 13 patients. Twenty-one patients had no PSA data for either date, whereas 62 patients had PSA levels determined at both 4 and 8 weeks
Univariate Analysts
The results of the univariate analysis of associations between pretreatment characteristics and survival from the 8-week landmark are listed in Table 2 . Five patients were excluded from these analyses because they died before the landmark. In addition, patients were also excluded because of rmssinmg information about the covariates. P in the table refers to the log-rank test, and the median survival estimates reported are from the 8-week landmark. Four factors were identified as associated with a statistically significant improvement in survival: pretreatment performance status (P < .0001), a relative decrease in PSA level of at least 50% by 8 weeks (P = .0005), a 75% or greater decrease in PSA level by 8 weeks (P = .0094), and baseline PSA level of 20 ng/ml or less (P = .0357). A 50% or greater decrease in PSA level at 4 weeks, a 75% or greater decrease at 4 weeks, the presence of measurable disease, and pretreatment alkaline phosphatase and hemoglobin levels were not predictors of survival in this analysis, although the baseline hemoglobin level approached statistical significance (P = .0594). Median survival from the landmark m the group with a PSA level decrease of at least 50% at 8 weeks was 91 weeks compared with 38 weeks in those without a 50% decrease. Patients with at least a 75% decrease in PSA level at the landmark had a median survival from that point of 129 weeks. Median survival was 46 weeks in those with a less than 75% decrease. Patients without symptoms at study entry (PS, 0) had a median survival of 121 weeks from the landmark compared with 42 weeks for patients with even minimal symptoms (PS, 1) and 20 weeks for those with a PS of 2 or greater. There was also a marked difference in median survival when the patients with significant anemia (baseline hemoglobin level < 10 g/dL; median survival, 28 weeks) were compared with those with no anemia (hemoglobin level > 12.8 g/dL; median survival, 81 weeks). Survival curves for the parameters associated with improved survival in this analysis and the baseline hemoglobin levels are shown in Figs 1-5. In addition to the factors listed in Table 2. we also examined age, baseline lactate dehydrogenase level, the number of prior hormonal therapy regimens, prior chemotherapy, prior primary radiotherapy, and prior palliative radiotherapy as factors for predicting survival from the landmark None of these factors was significant, even at the 40% (P < .4) level. 
Detennlnatlon of Best PSA Predictor of Survival
Having estabhshed the predictors of survival by univariate analysis, we next evaluated both the time to PSA decline and the degree of decline to determine the best predictor of survival. With data from the 62 patients who had PSA values at both 4 and 8 weeks, we tested a Cox model that predicted survival by PS and a PSA marker versus PS alone. The relative change in PSA was evaluated at both 4 and 8 weeks having a threshold effect at 50%. Baseline PSA value (P = .2754) was not a significant predictor of survival in this analysis despite its significance in the univariate analysis. In ntimuous variable and as two threshold effects at a contrast, a baseline hemoglobin level less than 10 g/dL greater and a 75% or greater decrease from baseline, emerged as a predictor for decreased survival in both the full sults of this analysis are listed in Table 3 . The best and reduced models. The reduced model concludes that the -edictor for survival from 8 weeks in this series was risk of death increased approximately twofold for each ual relative change in PSA level at 8 weeks (P = incremental increase in PS on the Zubrod scale, after For practical purposes in treating patients, a 50% or adjusting for change in PSA and baseline hemoglobin levels. decrease in PSA level at 8 weeks (P = .1158) was a
Patients with a less than 50% decrease in PSA level at 8 seful benchmark measure. Both the threshold value weeks had a near doubling in the risk of death compared continuous measure were considered in the developwith patients with a 50% or greater decrease, given that the If a multivariable survival model.
PS was the same. Patients with a baseline hemoglobin level liable Analysis less than 10 g/dL also had a doubling in the risk of death when compared with those with a hemoglobin level of at then constructed a multiple Cox regression model least 10 g/dL. 1I the non-PSA factors listed in Table 2 with a P less As a final step in the model-building process, the statistlincluded in the full model. (Table 4) . Data was cally important factors were checked for pairwise interacile in all categories for 73 patients. A backwards tion. There was a significant interaction between the baseline tion scheme was used to develop the model with the hemoglobin level and the PS. The results of this analysis and dictive power by removing the least predictive factor the resulting model are listed in Table 6 . The significant tially and refitting the model until all factors contribinteraction between PS and hemoglobin level requires that Abbreviatlon IA, Interaction associated with shorter survival only when the PS is 2 or greater. Specifically, among patients with a PS of 2 or greater, the risk of death for those who also have a hemoglobin level less than 10 g/dL is estimated to be 5.62 times higher than for those with a hemoglobin level of 10 g/dL or greater (P = 0007). However, for patients with a PS less than 2, this same risk ratio s estimated to be only 1.3 (P = .4850) It is important to note that a PSA level decrease of 50% or greater retains its association with improved survival independent of PS or hemoglobin level. When PSA is considered as a continuous variable, the overall results are very similar ( Table 7) . As before, the most predictive model adjusts for PS, baseline hemoglobin level, and their interaction. As an example, the risk ratio for a patient with a 30% decrease in PSA level at 8 weeks relative to a patient with a 50% decrease is estimated to be (0.99)30-50 = 1.22, or only 22% higher. The risk ratio for a patient with a 30% increase in PSA level at 8 weeks relative to a patient with a 50% decrease is estimated to be (0.99) -3 0-5 0 = 2.23, an increase in risk of 123%. Despite these obvious differences, both patients (30% increase and 30% decrease) are considered to have a less than 50% decrease when using each of the other models. In the final model (Table 6 ), the estimated risk of death for both patients relative to a patient with a 50% or greater decrease in PSA level at 8 weeks is 2 20, or a 120% increase in the risk of death. 
Correlation of PSA With Soft Tissue Response
Of the 41 patients with soft tissue disease, 33 were assessable for response by classic critena. Nineteen of these 33 patients had either a partial or complete response in measurable soft tissue, and this was associated with a 50% or greater decrease in PSA level at some point during therapy m 13 patients (P = .0369) Two additional patients had decreases in PSA levels with therapy, although this did not reach the 50% threshold. No PSA data were available m the remaining four patients who had evidence of response in soft tissue. There was no significant association between soft tissue response and a 50% or greater decline at the 8-week landmark (P = 1968). This analysis was limited by small sample size (23 patients with both PSA and soft tissue response data). Of these patients, the majority (54%) who had a soft tissue response also had a 50% or greater decrease m PSA level, whereas only 20% of those with no measurable response had a similar decrease in PSA level.
Consistency of PSA Values
Of the 75 patients who had PSA values available at 8 weeks, 31 patients had at least a 50% decrease at the landmark. Two patients had no subsequent PSA measurements recorded Of the remaining 29 patients, 27 patients (93%) had a 50% or greater decrease at their next measured PSA value. Fifteen patients did not have a 50% or greater decrease at 8 weeks, but did reach this level at some other time during therapy. Of these, only three patients had PSA values decreased to this level before 8 weeks, whereas 10 patients had a 50% decrease after 8 weeks These 10 patients all had significant decreases before the landmark but did not reach the threshold value The two remaining patients had 50% or greater decreases in PSA level both before and after the landmark, but not at the 8-week determination.
DISCUSSION
The treatment of hormone-refractory prostate cancer has long been complicated by a lack of effective treatment regimens and difficulty in assessing response. With the recent development of several new agents and combinations that have shown significant promise in the treatment of this disease, the first of these problems is being addressed Assessment of response, however, remains a difficult and contentious issue. Although it remains controversial, changes in serum PSA levels have become a defacto marker of response. This is despite less than universal agreement on the degree and duration of change in PSA level required for response. This approach has also introduced the potential bias of comparing responders and nonresponders, because the majority of these trials have not used specific landmarks to validate PSA level as a marker of response.
1 Data were analyzed from 110 assessable patients enrolled onto seven consecutive treatment programs that used cytotoxic agents alone or in combination (estramustine/vinblastine, trimetrexate, gemcitabine, suramin, and rhenium 186). Fifteen patients (14%) had a 50% or greater decrease in PSA level at 60 days. By using landmark analysis at that time point, a significantly longer median survival for patients with a 50% or greater decline in PSA level was shown compared with those who had a less than 50% decline. Multivariable analysis of these data showed that a 50% or greater decrease in PSA level (P = .0004) and the natural log of the lactate dehydrogenase level (P = .0001) were the two most significant vanables that predicted survival. Because of the subjectivity involved in assessing PS, these investigators chose to exclude this from their prognostic model. Pretreatment PSA level was not an important predictor of survival. Although the conclusions of this analysis can be questioned based on the varety of therapies used and the relatively low number of responders, the conclusion that PSA level is a valid marker of response is strengthened by the apphcation of the model to an independent data set.
Investigators at the University of Maryland have articulated a contrasting view as to the value of PSA as a marker of response. With data collected on two phase I studies of suramin that included patients with hormone-refractory prostate cancer, they analyzed the ability of PSA to predict response.
22 They chose as their landmark the PSA level at 4 weeks and showed no significant difference in survival for patients with either a 50% or greater or a 75% or greater decrease in PSA level at that point. By using a tree-based model with survival of I year as the decision criteria, they were also unable to show that any decline in PSA level after 4 weeks of therapy with suramin was a significant predictor of survival On multivanable analysis, they identified pretreatment hemoglobin level as a significant predictor of survival, with pretreatment PSA level and percentage change in PSA level from baseline to the measurement at 4 weeks as weak significant predictors of survival.
The reason or reasons for the disparity of these conclusions are not immediately apparent, but probably he in the significant differences in the types of therapy and the measurements used in these two analyses. The study from Memorial Sloan-Ketterming Cancer Center analyzed data from patients involved in seven different studies and had a relatively small number of responders (15 of 110 patients; 14%). These patients received a varety of chemotherapeutic regimens that included cytotoxic agents, suramin, and a radiolabeled compound that preferentially localizes the bone. In contrast, patients analyzed at the University of Maryland all received suramin, albeit at four different dose levels. The major issue in interpreting the data from the University of Maryland study, however, is an understanding of the delivery and mechanism of action of suramin. This drug has a long half-life and is delivered over a long treatment schedule (12 weeks).
26 By the landmark chosen for this analysis (4 weeks), patients had completed only one third of the planned duration of the therapy, although they had received the majority of the drug to be administered. With a documented half-life of approximately 56 days, tumor cells have a prolonged exposure to suramin, thus the early landmark chosen may not be optimal for this agent. A recent abstract appeared to support the contention that PSA level is not a reliable marker of response based on an analysis of PSA levels after 56 days of suramin therapy. 27 The mechanism of action of suramin, although not entirely clear, may also contribute to this confusing picture. Suramin has been shown to alter a number of cellular functions that include the binding of growth factors and cytokmnes to their receptors, 2 829 cellular motility, 30 and cellular energy balance. 31 Xenograft models have shown that at least one prostate cancer cell line can show progressive growth despite suramin-induced declines in serum PSA level. 32 The cell lines used in these xenograft models (LNCaP and C4-2) have been shown to have reduced expression of PSA mRNA after in vitro exposure to suramin. This may or may not be associated with tumor growth inhibition, which results m discordance between serum PSA levels and tumor status. Thus, both clinical and preclinical data suggest that PSA level is not an optimal marker for response after therapy with suramin. This may also be the case for other types of agents, such as differentiating agents that alter tumor growth without necessarily resulting in a reduction in tumor volume. In this setting, serum PSA levels may not be a surrogate marker for response. 33 Our analysis of the estramustme/etoposide tnals addresses some of the limitations of the two prior studies In our studies, a large number of patients were enrolled and received essentially the same cytotoxic therapy. Our analysis indicates that a 50% or greater decrease in PSA level at 8 weeks is associated with prolonged survival. Based on the likelihood ratios, it appears to be a better predictor than a 50% or greater decline at 4 weeks or a 75% or greater dechne at either 4 or 8 weeks. One limitation of this analysis is the fact that fully one third (39) of the patients enrolled onto these studies had no PSA value recorded at the landmark. In 19 of these patients, this was because of rapid disease progression or toxicity that resulted in them receiving less than 8 weeks of therapy. Four patients were lost to follow-up and had relatively short survival. The remaining sixteen patients all had at least stable disease but did not have a PSA value recorded at 8 weeks.
SMITH ET AL
Multivariable analysis confirmed a 50% or greater decrease in PSA level at 8 weeks as a prognostic marker for survival in this data set. In addition, PS and baseline hemoglobin values were significant prognostic markers, particularly in the setting of the combination of significant anemia (hemoglobin < 10 g/dL) and PS of 2 or greater on the Zubrod scale. The investigators at Memonal SloanKetterming Cancer Center chose to exclude PS from their multivariable model, citing the subjectivity associated with its measurements. The simplified scales with broader categories of measurement (ie, Zubrod, Eastern Cooperative Oncology Group, World Health Organization) are more easily applied than the Karnofsky scale. Given the significance of this measure in terms of predicting overall survival, it is difficult to exclude it from prognostic models. Our findings confirmed the univariate analyses of both the Memorial Sloan-Kettering Cancer Center and the University of Maryland data, which suggested that the PS at study entry is a significant factor in survival. Pretreatment PSA level was not a significant indicator in the multivanable analysis of our dataset or the Memonal Sloan-Kettering Cancer Center analysis. Both pretreatment PSA level and hemoglobin level had some prognostic significance in the University of Maryland analysis. The reason for this disparity is again unclear, but may relate to the treatment delivered rather than the disease itself. The finding that pretreatment PSA level is not an independent indicator of survival is somewhat surprising, given the evidence that suggests a correlation between PSA level and extent of disease. It implies that a decrease in serum PSA level from 10 ng/mL to 5 ng/mL is as significant as a dechne from 1,000 ng/mL to 500 ng/mL. One possible explanation for this observation is the inverse relationship between tumor differentiation and PSA production by tumor cells. The least differentiated and most aggressive tumors appear to produce relatively less circulating PSA despite the presence of the glycoprotein in tumor cells.
34
- 36 Highly aggressive tumors with high growth fractions may be widely disseminated despite relatively low levels of serum PSA 37 The rapid growth rate may also render these cells more susceptible to cytotoxic agents. Despite the lack of PSA secretion from these cells, it appears that changes in serum PSA levels with therapy may be a predictor of survival even for these tumors when they are treated with cytotoxic agents.
An interaction between pretreatment PS and baseline hemoglobin level was shown in the multivariable analysis of our data set. This interaction occurred at the extremes of these measures, which suggested an association between anemia and poor functional status. This observation fits well with clinical practice and points to the profound effect of anemia on the functional status of patients with prostate cancer. This Interaction may also account for the association between pretreatment hemoglobin level and survival seen in the University of Maryland study This analysis confirms the observation that a 50% or greater decline In the PSA level at 2 months (8 weeks, 60 days) is a predictor of survival in patients who received cytotoxic therapy for hormone-refractory prostate cancer. Decreases in PSA levels were consistent and confirmed on subsequent measurements in more than 90% of patients. This analysis also confirms the correlation of PSA level with the measurement of response in soft tissue disease and points to the importance of PS at study enrollment as a predictor of survival. Decreases in PSA levels to this threshold value are associated with prolonged survival in both patients with soft tissue disease and those with disease confined to the bone. We would argue that this criterion should be incorporated into the response assessment for future phase II trials of cytotoxic agents as well as in the reporting of response data from these trials. Our model will need to be validated by using an independent data set, but confirms the observations previously reported on the efficacy of PSA as an indicator of response to chemotherapy. Caution should be used in interpreting changes in PSA levels after therapy with agents such as suramin, which inhibit tumor growth through other mechanisms.
